乳腺癌幸存者的心肌梗死、心力衰竭和肿瘤预后

IF 12 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS
Oscar Calvillo-Argüelles MD , Paaladinesh Thavendiranathan MD, SM , Yue Chen MScPH , Jiming Fang PhD , Peter C. Austin PhD , Eitan Amir MD, PhD , Douglas S. Lee MD, PhD , Husam Abdel-Qadir MD, PhD
{"title":"乳腺癌幸存者的心肌梗死、心力衰竭和肿瘤预后","authors":"Oscar Calvillo-Argüelles MD ,&nbsp;Paaladinesh Thavendiranathan MD, SM ,&nbsp;Yue Chen MScPH ,&nbsp;Jiming Fang PhD ,&nbsp;Peter C. Austin PhD ,&nbsp;Eitan Amir MD, PhD ,&nbsp;Douglas S. Lee MD, PhD ,&nbsp;Husam Abdel-Qadir MD, PhD","doi":"10.1016/j.jaccao.2024.08.008","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Cardiovascular disease (CVD) is associated with higher rates of incident cancer. Data are scarce regarding the association of incident CVD with oncologic outcomes after a cancer diagnosis.</div></div><div><h3>Objectives</h3><div>This study sought to determine whether incident myocardial infarction (MI) or heart failure (HF) in breast cancer survivors is associated with oncologic outcomes.</div></div><div><h3>Methods</h3><div>This was a population-based cohort study in Ontario, Canada, using linked administrative data sets of women diagnosed with first breast cancer between April 1, 2007, and March 31, 2015. A landmark analysis was conducted of women alive 2 years after breast cancer diagnosis, aged ≥40 years, and with available staging data and without recurrent/distant disease or preceding CVD. The exposure was a composite of MI and/or HF after the landmark date. The outcomes were cancer mortality, new non-breast malignancy diagnosis, and new chemotherapy initiation. Multivariable cause-specific hazards regression was used to determine the association of incident MI/HF (time-varying exposure) with outcomes.</div></div><div><h3>Results</h3><div>A total of 30,694 women (median age of 60 years) were included, of whom 1,346 developed incident MI/HF at a median of 3.9 years after the landmark date. At 5 years, the cumulative incidence was 5.9% (95% CI: 5.6%-6.1%) for cancer death, 4.3% (95% CI: 4.1%-4.6%) for non-breast malignancy, and 25.7% (95% CI: 25.2%-26.2%) for new chemotherapy. Incident MI/HF was associated with a higher hazard of cancer death (HR: 3.94; 95% CI: 3.38-4.59), non-breast malignancy (HR: 1.39; 95% CI: 1.06-1.82), and new chemotherapy (HR: 1.25; 95% CI: 1.02-1.53).</div></div><div><h3>Conclusions</h3><div>Incident MI and/or HF after breast cancer treatment are associated with higher hazards of adverse oncologic outcomes, highlighting the need to prioritize care for these patients.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 6","pages":"Pages 893-903"},"PeriodicalIF":12.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711813/pdf/","citationCount":"0","resultStr":"{\"title\":\"Incident Myocardial Infarction, Heart Failure, and Oncologic Outcomes in Breast Cancer Survivors\",\"authors\":\"Oscar Calvillo-Argüelles MD ,&nbsp;Paaladinesh Thavendiranathan MD, SM ,&nbsp;Yue Chen MScPH ,&nbsp;Jiming Fang PhD ,&nbsp;Peter C. Austin PhD ,&nbsp;Eitan Amir MD, PhD ,&nbsp;Douglas S. Lee MD, PhD ,&nbsp;Husam Abdel-Qadir MD, PhD\",\"doi\":\"10.1016/j.jaccao.2024.08.008\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Cardiovascular disease (CVD) is associated with higher rates of incident cancer. Data are scarce regarding the association of incident CVD with oncologic outcomes after a cancer diagnosis.</div></div><div><h3>Objectives</h3><div>This study sought to determine whether incident myocardial infarction (MI) or heart failure (HF) in breast cancer survivors is associated with oncologic outcomes.</div></div><div><h3>Methods</h3><div>This was a population-based cohort study in Ontario, Canada, using linked administrative data sets of women diagnosed with first breast cancer between April 1, 2007, and March 31, 2015. A landmark analysis was conducted of women alive 2 years after breast cancer diagnosis, aged ≥40 years, and with available staging data and without recurrent/distant disease or preceding CVD. The exposure was a composite of MI and/or HF after the landmark date. The outcomes were cancer mortality, new non-breast malignancy diagnosis, and new chemotherapy initiation. Multivariable cause-specific hazards regression was used to determine the association of incident MI/HF (time-varying exposure) with outcomes.</div></div><div><h3>Results</h3><div>A total of 30,694 women (median age of 60 years) were included, of whom 1,346 developed incident MI/HF at a median of 3.9 years after the landmark date. At 5 years, the cumulative incidence was 5.9% (95% CI: 5.6%-6.1%) for cancer death, 4.3% (95% CI: 4.1%-4.6%) for non-breast malignancy, and 25.7% (95% CI: 25.2%-26.2%) for new chemotherapy. Incident MI/HF was associated with a higher hazard of cancer death (HR: 3.94; 95% CI: 3.38-4.59), non-breast malignancy (HR: 1.39; 95% CI: 1.06-1.82), and new chemotherapy (HR: 1.25; 95% CI: 1.02-1.53).</div></div><div><h3>Conclusions</h3><div>Incident MI and/or HF after breast cancer treatment are associated with higher hazards of adverse oncologic outcomes, highlighting the need to prioritize care for these patients.</div></div>\",\"PeriodicalId\":48499,\"journal\":{\"name\":\"Jacc: Cardiooncology\",\"volume\":\"6 6\",\"pages\":\"Pages 893-903\"},\"PeriodicalIF\":12.0000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711813/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Jacc: Cardiooncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666087324003478\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Jacc: Cardiooncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666087324003478","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

背景:心血管疾病(CVD)与较高的癌症发病率有关。有关癌症确诊后心血管疾病事件与肿瘤结果之间关系的数据很少:本研究旨在确定乳腺癌幸存者的心肌梗死(MI)或心力衰竭(HF)事件是否与肿瘤结果有关:这是一项在加拿大安大略省进行的基于人群的队列研究,使用的是2007年4月1日至2015年3月31日期间首次诊断为乳腺癌的女性的关联管理数据集。对乳腺癌确诊后 2 年仍存活、年龄≥40 岁、有分期数据、无复发/远处疾病或既往有心血管疾病的女性进行了标志性分析。风险暴露是地标日期后心肌梗死和/或高血压的复合风险。研究结果包括癌症死亡率、新诊断出的非乳腺恶性肿瘤和新开始的化疗。采用多变量特异性病因危险度回归法来确定心肌梗死/心房颤动事件(时变暴露)与结果之间的关系:共纳入了 30,694 名妇女(中位年龄为 60 岁),其中 1,346 人在地标日期后的 3.9 年中发生了心肌梗死/心房颤动。5年后,癌症死亡的累积发病率为5.9%(95% CI:5.6%-6.1%),非乳腺恶性肿瘤的累积发病率为4.3%(95% CI:4.1%-4.6%),新化疗的累积发病率为25.7%(95% CI:25.2%-26.2%)。发生心肌梗死/房颤与癌症死亡(HR:3.94;95% CI:3.38-4.59)、非乳腺恶性肿瘤(HR:1.39;95% CI:1.06-1.82)和新化疗(HR:1.25;95% CI:1.02-1.53)的较高风险相关:结论:乳腺癌治疗后发生心肌梗死和/或高血压与较高的不良肿瘤预后风险相关,因此需要优先照顾这些患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Incident Myocardial Infarction, Heart Failure, and Oncologic Outcomes in Breast Cancer Survivors

Background

Cardiovascular disease (CVD) is associated with higher rates of incident cancer. Data are scarce regarding the association of incident CVD with oncologic outcomes after a cancer diagnosis.

Objectives

This study sought to determine whether incident myocardial infarction (MI) or heart failure (HF) in breast cancer survivors is associated with oncologic outcomes.

Methods

This was a population-based cohort study in Ontario, Canada, using linked administrative data sets of women diagnosed with first breast cancer between April 1, 2007, and March 31, 2015. A landmark analysis was conducted of women alive 2 years after breast cancer diagnosis, aged ≥40 years, and with available staging data and without recurrent/distant disease or preceding CVD. The exposure was a composite of MI and/or HF after the landmark date. The outcomes were cancer mortality, new non-breast malignancy diagnosis, and new chemotherapy initiation. Multivariable cause-specific hazards regression was used to determine the association of incident MI/HF (time-varying exposure) with outcomes.

Results

A total of 30,694 women (median age of 60 years) were included, of whom 1,346 developed incident MI/HF at a median of 3.9 years after the landmark date. At 5 years, the cumulative incidence was 5.9% (95% CI: 5.6%-6.1%) for cancer death, 4.3% (95% CI: 4.1%-4.6%) for non-breast malignancy, and 25.7% (95% CI: 25.2%-26.2%) for new chemotherapy. Incident MI/HF was associated with a higher hazard of cancer death (HR: 3.94; 95% CI: 3.38-4.59), non-breast malignancy (HR: 1.39; 95% CI: 1.06-1.82), and new chemotherapy (HR: 1.25; 95% CI: 1.02-1.53).

Conclusions

Incident MI and/or HF after breast cancer treatment are associated with higher hazards of adverse oncologic outcomes, highlighting the need to prioritize care for these patients.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
12.50
自引率
6.30%
发文量
106
期刊介绍: JACC: CardioOncology is a specialized journal that belongs to the esteemed Journal of the American College of Cardiology (JACC) family. Its purpose is to enhance cardiovascular care for cancer patients by publishing high-quality, innovative scientific research and sharing evidence-based knowledge. The journal aims to revolutionize the field of cardio-oncology and actively involve and educate professionals in both cardiovascular and oncology fields. It covers a wide range of topics including pre-clinical, translational, and clinical research, as well as best practices in cardio-oncology. Key areas of focus include understanding disease mechanisms, utilizing in vitro and in vivo models, exploring novel and traditional therapeutics (across Phase I-IV trials), studying epidemiology, employing precision medicine, and investigating primary and secondary prevention. Amyloidosis, cardiovascular risk factors, heart failure, and vascular disease are some examples of the disease states that are of particular interest to the journal. However, it welcomes research on other relevant conditions as well.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信